Drugs / CDX-585
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05788484 | May 2023 → May 2025 | cholangiocarcinoma, colorectal cancer, esophageal cancer, fallopian tube cancer +8 | Celldex Therapeutics | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-11-12 | Celldex Therapeutics | Results Celldex Presents Positive Preclinical Data from PD-1/ILT4 Bispecific Antibody Program CDX-585 at SITC 2021 celldex.com ↗
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced positive preclinical data from CDX-585, the Company’s bispecific antibody with dual targeting of ILT4 and PD-1 checkpoint pathways, developed from its bispecific antibody platform. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-05-31 | Celldex Therapeutics | Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies celldex.com ↗ |
| 2021-11-12 | Celldex Therapeutics | Celldex Presents Positive Preclinical Data from PD-1/ILT4 Bispecific Antibody Program CDX-585 at SITC 2021 celldex.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CDX-585 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05788484 ↗ |